Harnessing Antitumor Immunity in Ovarian Cancer

IF 7.8 2区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Cold Spring Harbor perspectives in medicine Pub Date : 2024-04-15 DOI:10.1101/cshperspect.a041336

Katherine C. Kurnit, Kunle Odunsi

引用次数: 0

Abstract

Despite progress in other tumor types, immunotherapy is not yet part of the standard of care treatment for high-grade serous ovarian cancer patients. Although tumor infiltration by T cells is frequently observed in patients with ovarian cancer, clinical responses to immunotherapy remain low. Mechanisms for immune resistance in ovarian cancer have been explored and may provide insight into future approaches to improve response to immunotherapy agents. In this review, we discuss what is known about the immune landscape in ovarian cancer, review the available data for immunotherapy-based strategies in these patients, and provide possible future directions.

查看原文本刊更多论文

利用卵巢癌的抗肿瘤免疫力

尽管在其他肿瘤类型中取得了进展，但免疫疗法尚未成为高级别浆液性卵巢癌患者的标准治疗方法之一。虽然在卵巢癌患者中经常观察到 T 细胞浸润肿瘤的现象，但免疫疗法的临床反应仍然很低。人们对卵巢癌免疫耐受的机制进行了探索，这可能会为未来改善免疫治疗药物反应的方法提供启示。在这篇综述中，我们将讨论卵巢癌免疫环境的已知情况，回顾这些患者基于免疫疗法策略的现有数据，并提供未来可能的发展方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cold Spring Harbor perspectives in medicine MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

14.30

自引率

1.90%

发文量

审稿时长

4-8 weeks

期刊介绍： Cold Spring Harbor Perspectives in Medicine is a monthly online publication comprising reviews on different aspects of a variety of diseases, covering everything from the molecular and cellular bases of disease to translational medicine and new therapeutic strategies. Cold Spring Harbor Perspectives in Medicine is thus unmatched in its depth of coverage and represents an essential source where readers can find informed surveys and critical discussion of advances in molecular medicine.